



SEQUENCE LISTING

<110> BRANDT, CURTIS R.
BULTMANN, HERMANN

<120> PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS
OF THEIR USE

<130> 032026-0460

<140> 09/777,560
<141> 2001-02-06

<150> 60/184,057
<151> 2000-02-22

<150> 60/180,823
<151> 2000-02-07

<160> 32

<170> PatentIn Ver. 3.2

<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1
Arg Arg Lys Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala
1 5 10 15

Leu Leu Ala Pro
20

<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2
Arg Arg Lys Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala
1 5 10 15

Leu Leu Ala Pro
20

<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 3
Arg Arg Lys Lys Ala Ala Val Ala Leu Leu Ala Val Leu Leu Ala Leu
1 5 10 15

Leu Ala Pro Pro
20

<210> 4
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 4
Arg Arg Lys Lys Pro Ala Val Leu Leu Ala Leu Leu Ala
1 5 10

<210> 5
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 5
Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
1 5 10 15

Leu Ala

<210> 6
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (11)..(12)
<223> D-form amino acid

<400> 6
Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Ala Leu Lys
1 5 10 15

Leu Ala

<210> 7
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 7
Arg Gln Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

Pro Gly Tyr Ala Gly Ala Val Val Asn Asp Leu
20 25

<210> 8
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(16)
<223> D-form amino acid

<400> 8
Arg Gln Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 9
Arg Gln Ile Lys Ile Phe Phe Pro Asn Arg Arg Met Lys Phe Lys Lys
1 5 10 15

<210> 10
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 10
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Gly Tyr Ala Gly
1 5 10 15

Ala Val Val Asn Asp Leu
20

<210> 11
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Gly Asp Val Tyr
1 5 10 15

Ala Asn Gly Leu Val Ala
20

<210> 12
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 12
Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
20 25

<210> 13

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 13

Asp Pro Lys Gly Asp Pro Lys Gly Val Thr Val Thr Val Thr
1 5 10 15

Val Thr Gly Lys Gly Asp Pro Lys Pro Asp
20 25

<210> 14

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Formula peptide

<220>

<221> MOD_RES

<222> (1)..(10)

<223> charged amino acid; e.g. Lys or Arg; this region may encompass either 0 or 3-10 Xaa repeats with the proviso that in one embodiment either residues 1-10 are not present or residues 27-36 are not present

<220>

<221> MOD_RES

<222> (27)..(36)

<223> charged amino acid; e.g. Lys or Arg; this region may encompass either 0 or 3-10 Xaa repeats with the proviso that in one embodiment either residues 1-10 are not present or residues 27-36 are not present

<400> 14

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Ala Val Ala Leu Leu
1 5 10 15

Pro Ala Val Leu Leu Ala Leu Leu Ala Pro Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa
35

<210> 15

<211> 29

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Formula
peptide

<220>
<221> MOD_RES
<222> (1)..(10)
<223> charged amino acid; e.g. Lys or Arg; this region may encompass either 0 or 3-10 Xaa repeats with the proviso that in one embodiment either residues 1-10 are not present or residues 20-29 are not present

<220>
<221> MOD_RES
<222> (20)..(29)
<223> charged amino acid; e.g. Lys or Arg; this region may encompass either 0 or 3-10 Xaa repeats with the proviso that in one embodiment either residues 1-10 are not present or residues 20-29 are not present

<400> 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Pro Ala Val Leu Leu Ala
1 5 10 15

Leu Leu Ala Xaa
20 25

<210> 16
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 16
Arg Arg Lys Lys
1

<210> 17
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 17
Arg Arg Lys Lys Leu Ala Ala Leu Pro Leu Val Leu Ala Ala Pro Leu
1 5 10 15

Ala Val Leu Ala
20

<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 18
Arg Arg Lys Lys Ala Ala Val Ala Leu Leu Pro
1 5 10

<210> 19
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 19
Arg Arg Lys Lys Ala Val Ala Val Ala Val Pro Ala Val Leu Leu Ala
1 5 10 15

Leu Leu Ala Pro
20

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20
Arg Arg Lys Lys Pro Ala Val Leu Leu Ala
1 5 10

<210> 21
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 21
Arg Arg Lys Lys Pro Ala Val Leu Leu Ala Leu Leu Ala
1 5 10

<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 22
Arg Arg Lys Lys Pro Ala Val Leu Leu Ala Leu Leu Ala Leu Ala
1 5 10 15

<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 23
Arg Arg Lys Lys Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala
1 5 10 15

Pro

<210> 24
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 24
Arg Arg Lys Lys Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10

<210> 25
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 25
Arg Arg Lys Lys Leu Leu Ala Leu Leu Ala Pro
1 5 10

<210> 26
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 26
Arg Arg Lys Lys Leu Leu Ala Pro
1 5

<210> 27
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 27
Arg Arg Lys Lys Ala Ala Val Ala Leu Leu Pro Ala Val Leu Ala
1 5 10 15

Leu

<210> 28
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 28
Arg Arg Lys Lys Ala Ala Val Ala Val Val Pro Ala Val Leu
1 5 10

<210> 29
<211> 11

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 29
Arg Arg Lys Lys Ala Ala Val Ala Val Val Pro
1 5 10

<210> 30
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 30
Arg Arg Lys Lys Ala Ala Val Ala
1 5

<210> 31
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 31
Pro Gly Tyr Ala Gly Ala Val Val Asn Asp Leu
1 5 10

<210> 32
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 32
Pro Gly Asp Val Tyr Ala Asn Gly Leu Val Ala
1 5 10